These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 32368173)
1. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy. Khan OF; Monzon J Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173 [TBL] [Abstract][Full Text] [Related]
2. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543 [TBL] [Abstract][Full Text] [Related]
3. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Okiyama N; Tanaka R Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349 [TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663 [TBL] [Abstract][Full Text] [Related]
5. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. Yao J; Li M; Zhang H; Ge Y; Weygant N; An G Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598 [TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495 [TBL] [Abstract][Full Text] [Related]
7. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. Yao L; Jia G; Lu L; Bao Y; Ma W Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388 [TBL] [Abstract][Full Text] [Related]
8. How can we manage the cardiac toxicity of immune checkpoint inhibitors? Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484 [No Abstract] [Full Text] [Related]
9. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210 [TBL] [Abstract][Full Text] [Related]
11. Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity. Hendekli CM J Cancer Res Clin Oncol; 2023 Sep; 149(11):9375-9398. PubMed ID: 37076644 [TBL] [Abstract][Full Text] [Related]
12. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Weinmann SC; Pisetsky DS Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080 [TBL] [Abstract][Full Text] [Related]
15. Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events. Yan T; Yu L; Zhang J; Chen Y; Fu Y; Tang J; Liao D Front Immunol; 2024; 15():1292122. PubMed ID: 38410506 [TBL] [Abstract][Full Text] [Related]
16. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432 [TBL] [Abstract][Full Text] [Related]
17. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article. Chen CH; Yu HS; Yu S Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208 [TBL] [Abstract][Full Text] [Related]
18. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. Sandigursky S; Mor A Curr Rheumatol Rep; 2018 Sep; 20(10):65. PubMed ID: 30191417 [TBL] [Abstract][Full Text] [Related]
20. Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Xu Y; Wen N; Sonis ST; Villa A Cancer; 2021 Jun; 127(11):1796-1804. PubMed ID: 33595843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]